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AKI biomarker would have nor ma lized 
within 24  h when sampling was per formed. 
An alternative explanation is that the 
performance of all urinary biomark ers, 
including NGAL, is reduced and delayed in 
patients with chronic kidney disease 
(CKD). 12 Our analysis of plasma NGAL 
data in the EARLYARF study 12,13 showed a 
similar dependence of performance on base-
line renal function and duration of injury to 
the urinary markers (unpublished data). 
Thus, although Zimmerman  et al. 11 
collected NGAL data at the potentially 
optimal time of 3  h aft er bypass, that time is 
not optimal for patients with CKD! Th us 
inclusion of patients with baseline CKD has 
the eff ect of creating a more realistic but also 
more heterogeneous population from a 
biomarker perspective. Stratifying for base-
line renal function would require a much 
larger number of patients. For these reasons, 
the NGAL results were unhelpful in both 
studies in detecting renal injury independ-
ently of change in serum creatinine. 
 Overall, the results of RIPC in these two 
studies 10,11 appear consistent with the pro-
pensity for development of AKI in the 
patient cohorts studied. The lower the 
expected incidence of AKI, the larger the 
study required to assess renal protection. 
CKD is a well-known risk factor for AKI 
and is present in approximately 30 % of 
cases. We should therefore be encouraged 
by the outcome in the more realistic popu-
lation in the Zimmerman  et al. pilot study 
in patients reported here, 11 in which 16 % 
had underlying CKD (estimated glomeru-
lar filtration ate   <  60  ml / min / 1.73  m 2 ). 
Nevertheless, the dose and type of ischemic 
preconditioning needed are not yet estab-
lished, and the eff ects of age, drugs, and 
comorbidity on the response to RIPC await 
validation in much larger multicenter stud-
ies. It remains to be seen whether renal 
protection is independent of improving 
myocardial function with RIPC. 
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 Immunosuppressive 
treatment of focal segmental 
glomerulosclerosis: lessons from 
a randomized controlled trial 
 Jeroen K.J.  Deegens 1 and  Jack F.M.  Wetzels 1 
 Patients with steroid-resistant focal segmental glomerulosclerosis 
(FSGS) may benefit from treatment with calcineurin inhibitors. 
A National Institutes of Health – funded FSGS multicenter study has 
suggested that a combination of mycophenolate mofetil and oral 
dexamethasone pulses was equivalent to cyclosporine. However, since 
the study was underpowered, one cannot draw firm conclusions from 
this study. The FSGS trial underscores that FSGS is not one disease and 
that better predictors of outcome and response to therapy are needed. 
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underlying cause). 1 In recent years, many 
new causes of FSGS have been identifi ed. 
Th e prognosis of FSGS is predicted by the 
severity and persistence of proteinuria, with 
60 % of patients with persistent nephrotic-
range proteinuria progressing to end-stage 
renal disease within 5 – 10 years. 2 Achieve-
ment of a remission, whether spontaneous 
or induced by immunosuppressive therapy, 
is associated with a good outcome. 1 
 Although there is no evidence from ran-
domized controlled trials, corticosteroids 
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 Focal segmental glomerulosclerosis (FSGS) 
is one of the most common patterns of 
glomerular injury and an important cause 
of end-stage renal disease in both adults 
and children. FSGS can be idiopathic 
(with unknown cause) or secondary (with 
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are currently the recommended fi rst-line 
treatment in patients with idiopathic FSGS 
and a nephrotic syndrome. 1 Remission 
rates vary from 31 to 74 % , depending on 
initial renal function, the pathological 
variant of FSGS (with the  ‘ tip ’ lesion carry-
ing the more favorable prognosis and the 
 ‘ collapsing ’ lesion the worst prognosis), the 
extent of interstitial fibrosis on renal 
biopsy, and dose and duration of and 
response to steroid treatment. Patients 
resistant to corticosteroids may respond to 
treatment with calcineurin inhibitors such 
as cyclosporine (CsA). Unfortunately, pro-
longed treatment with CsA may actually 
cause progressive renal injury, particularly 
when used in high dosage (>5.5  mg / kg / d) 
and in patients with preexisting renal insuf-
fi ciency. To assess alternative treatments 
for steroid-resistant FSGS (SR-FSGS), a 
National Institutes of Health – funded mul-
ticenter randomized controlled trial was 
conducted to evaluate whether treatment 
with mycophenolate mofetil (MMF) and 
oral pulses of dexamethasone (DEXA) was 
more eff ective than treatment with CsA. 3 
 Th e baseline characteristics of the FSGS 
Clinical Trial (FSGS-CT) have recently been 
published. 4 Th e trial included a total of 138 
patients between the ages of 2 and 40 years, 
and the authors are to be commended for 
conducting the largest study to date examin-
ing SR-FSGS. Still, the total number of patients 
included in the study was substantially lower 
compared with the study ’ s original design of 
500 randomized patients, which illustrates the 
diffi  culties of executing randomized control-
led trials in patients with FSGS. Th e patients 
were randomized at 53 sites, that is, an average 
of 2.5 patients per center. Although it is 
unknown how many patients with FSGS were 
seen in these centers in the study period, the 
low average suggests inclusion bias. 
 Gipson  et al. 3 (this issue) now report the 
main results of the FSGS-CT. At the end of 
the 52-week treatment period, the incidence 
of complete and partial remissions was 33 % 
in the MMF  +  DEXA group compared with 
46 % in the CsA group, a not signifi cant dif-
ference. To assess changes in proteinuria as 
primary outcome, the study used a six-level 
categorical variable. Th is is a novel assess-
ment standard. It is currently unknown 
whether this classifi cation allows a better 
analysis of the results. Moreover, it is ques-
tionable whether prognosis is signifi cantly 
diff erent with a score of 4 (a remission at 
week 26, but not at week 52) compared with 
a score of 5 or 6 (no remission at week 26). 
Nevertheless, even with the use of standard 
statistics the results remain unchanged. Th e 
odds ratio for developing a remission with 
MMF  +  DEXA (score of 1, 2, or 3) was 0.59 
(95 % confi dence interval 0.30 – 1.18). Th e 
wide confi dence interval refl ects the low 
power of the study and indicates that CsA 
treatment might be superior. 
 However, the results of the study are 
diffi  cult to interpret. A critical analysis 
reveals limitations that may prohibit its 
application in the treatment of the indi-
vidual patient with FSGS. 
 Th e defi nition of steroid resistance allowed 
inclusion of patients who received prednisone 
for only 4 weeks. Many studies in children use 
8 weeks, and in adults the median time to a 
remission is 3 months. 1 Th us, it is likely that 
(many) patients were included who would 
have responded to a longer duration of pred-
nisone therapy. If these patients are excluded, 
the response to MMF  +  DEXA may be even 
lower than reported. Moreover, the study 
population was quite heterogeneous: the 
study included children and adults, whites 
and African-Americans, patients with and 
without a family history of FSGS, and patients 
with normal and increased body mass index 
(up to 40  kg / m 2 was allowed). Furthermore, 
we do not know use of and response to previ-
ous immunosuppressive therapy (primary 
versus secondary steroid resistance). All these 
factors infl uence response to therapy and out-
come (see below). 
 During the study period the inclusion cri-
teria were changed, allowing treatment of 
patients who fulfi lled the defi nition of partial 
remission. Twenty-four percent of patients 
had proteinuria of 1 – 1.99 g / d, and it can be 
estimated that approximately 40 % of patients 
had proteinuria less than 3.5  g / d. We have no 
information about whether these patients 
ever had nephrotic-range proteinuria. Previ-
ous studies have shown that the prognosis of 
adults and children with a partial remission 
or non-nephrotic proteinuria at baseline is 
good, with 5-year renal survival of about 
90 % . 2,5 Most physicians would not use 
immunosuppressive treatment in these 
patients. Moreover, some patients with a 
partial remission may have residual pro-
teinuria due to secondary FSGS, which is 
unlikely to respond to immunosuppressive 
drugs. Th us, the inclusion of non-nephrotic 
patients, who were most likely to be classi-
fi ed as having treatment failure, may have 
concealed a beneficial effect of either 
MMF  +  DEXA or CsA in patients with 
nephrotic-range proteinuria. 
 Th ere are other relevant factors that may 
explain the seemingly unfavorable outcome 
in this study. One is the strict defi nition of 
partial remission. In the FSGS-CT a partial 
remission was defi ned by a reduction of pro-
teinuria of more than 50 % to a value 
between 0.2 and 2.0  g / d. Th is defi nition dif-
fers from that used in previous studies that 
defi ned partial remission as a decline in pro-
teinuria of more than 50 % to a value less 
than 3.5  g / d. 2,6,7 As a result, patients who 
started with a proteinuria of 8  g / d that 
decreased to 3  g / d at week 26 were classifi ed 
as having treatment failure, and study med-
ication was discontinued. Troyanov  et al. 
showed that these patients, whom they clas-
sifi ed as having partial remission, have a 
good prognosis. 2 Secondly, all patients who 
relapsed were considered as having treat-
ment failure. Although rescue treatment was 
allowed, this was not used, for unknown 
reasons. Th us, outcome in the FSGS-CT is 
based foremost on the 73 patients with treat-
ment failure at 26 weeks, many of whom 
might have benefi ted from continued or 
additional immunosuppressive therapy. 
 Th e FSGS trial used a combination of 
MMF  +  DEXA; it is therefore diffi  cult to 
attribute a benefi cial eff ect, if any, to an indi-
vidual drug or to the combination. Th us far, 
MMF has not been used as monotherapy in 
patients with steroid-resistant nephrotic 
syndrome (SRNS). Th e effi  cacy of MMF 
combined with low-dose prednisone has 
been negligible or very limited in patients 
with SRNS or SR-FSGS. In an uncontrolled 
study, Cattran  et al. reported a persistent 
partial remission in three of 18 patients, but 
none developed a complete remission. 8 Bet-
ter results were obtained by Li  et al. , who 
reported a remission rate of 87 % (complete 
in 62 % ). 9 However, this study included 
patients aged  < 2 years, most with late ster-
oid resistance, and all received concomitant 
high-dose steroids. Th us, we cannot draw 
conclusions on the added benefi t of MMF. 
In fact, prolonged therapy with steroids 
and / or the use of high-dose intravenous 
methylprednisolone or oral DEXA has been 
shown to cause remissions at a rate similar 
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to that achieved by the combination of 
MMF  +  DEXA reported in the FSGS-CT 
(Supplementary Table S1 online). 
 Th e FSGS trial confi rms the benefi ts of 
CsA in SR-FSGS. Th e effi  cacy of CsA in 
inducing remissions has been shown pre-
viously in randomized controlled trials 
(Supplementary Table S2 online) and 
many uncontrolled cohort studies. Tac-
rolimus is likely as effective as CsA. 10 
Importantly, the use of CsA also prevented 
deterioration of renal function (Supple-
mentary Table S2 online). It is unclear 
whether CsA should be combined with 
steroids, although data suggest that CsA 
is more effective when combined with 
prednisone. 11 Supplementary Table S2 
online illustrates that CsA with high-dose 
prednisone may be even better. 
 Th e current uncertainty about the optimal 
treatment and outcome of FSGS can be 
explained by the heterogeneity of the disease. 
FSGS is considered a podocyte disease. How-
ever, there are many causes of podocyte 
injury, as illustrated in  Figure 1 . Th e underly-
ing cause determines the effi  cacy of potential 
therapy. On one hand, we have the typical 
white patient with nephrotic syndrome, 
FSGS on renal biopsy, and podocyte foot 
process effacement, with a B or T cell-
dependent disease, which explains the initial 
response to steroids and the response to high-
dose methylprednisolone or even cyclophos-
phamide when the disease is becoming late 
resistant (secondary steroid resistance). 
On the other hand, there is the patient with 
obesity-related FSGS, with nephrotic-range 
proteinuria, normal serum albumin levels, 
and preserved foot processes, who will not 
respond to steroids (initial steroid resistance) 
but will benefi t from weight loss, angiotensin-
converting enzyme inhibitors, and, possibly, 
antifi brotic medication. Similarly, African-
Americans may respond less to steroids but 
may respond better to angiotensin-convert-
ing enzyme inhibitors. We know that the 
recurrence rate aft er transplantation is lower 
in African-Americans, indicative of a diff er-
ent pathogenesis. In this respect, FSGS in 
African-Americans has been associated with 
mutations in the  APOL1 gene. 12 Further-
more, in some patients CsA or high-dose 
DEXA but not standard immunosuppressive 
drugs may be eff ective, because of a direct 
effect of CsA and DEXA on podocyte 
function. Th e antiproteinuric eff ect of CsA 
appears to be related to a stabilization of 
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 Figure 1  |  The heterogeneity of focal segmental glomerulosclerosis. The figure illustrates that FSGS is not one disease but represents a spectrum of various 
causes of glomerular injury. In addition, patients may present in different stages of injury. As a result, studies may report variable responses to specific treatment 
modalities and different outcomes, depending on the composition of the study population. Thus, patients may present with a severe nephrotic syndrome, 
with nephrotic-range proteinuria, or merely with low-grade proteinuria. Although podocyte injury is considered pivotal in the development of FSGS, there 
are many different causes of podocyte injury. Immunological mechanisms are involved in idiopathic FSGS. These patients may respond to treatment directed 
at the immune system. Several  ‘ immunosuppressive ’ drugs (dexamethasone and cyclosporine) may also be effective in non-immune-mediated FSGS by 
directly targeting the podocyte. Alternative therapies are aimed at blocking factors involved in progressive glomerulosclerosis and interstitial fibrosis. 
APOL1, apolipoprotein L-1; CD2AP, CD2-associated protein; CLC-1, cardiotrophin-like cytokine factor 1; GS, glomerulosclerosis; IF / TA, interstitial fibrosis / tubular 
atrophy; ILK, integrin-linked kinase; PLCE1, phospholipase C  1; SCARB2, scavenger receptor class B, member 2; SuPAR, soluble urokinase receptor; TRPC-6, 
transient receptor potential 6; WT-1, Wilms tumor-1.  * Some of these agents may also target the podocyte. 
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the actin cytoskeleton in podocytes. 13 Th e 
same may be true for high-dose DEXA. 14 
 Currently, the treatment of FSGS can be 
considered as a voyage between Scylla and 
Charybdis. On one hand, we need to use 
prolonged aggressive therapy in patients 
with idiopathic FSGS who may respond, 
although response may take at least 4 
months of therapy. On the other hand, many 
patients with FSGS do not have idiopathic 
FSGS and will not respond to conventional 
immunosuppressive therapy, and such expo-
sure will put these patients at risk. Th e debate 
on the best treatment options for FSGS will 
continue. Since FSGS is not one disease, it is 
not surprising that the literature data on 
FSGS are so heterogeneous, results being 
dependent on the composition of the study 
population. Th e FSGS trial clearly illustrates 
that randomized controlled trials are diffi  -
cult to perform. Before embarking on new 
intervention studies, we need to develop bet-
ter clinical definitions for patients with 
FSGS, based on strict diagnostic and prog-
nostic criteria. Prospective registry data 
could provide these criteria. In addition, 
studies must be directed at identifying risk 
markers for progression and outcome. 
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 SUPPLEMENTARY MATERIAL 
 Table S1. Remission rate in studies in patients 
with steroid resistant FSGS using prolonged 
and / or high dose corticosteroid therapy. 
 Table S2. Remission rate in studies in 
patients with steroid resistant FSGS using 
calcineurin inhibitors with / without high dose 
corticosteroids.
Supplementary material is linked to the 
online version of the paper at  http://www.
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 Transplant glomerulopathy: it ’ s 
not always about chronic rejection 
 Mark  Haas 1 
 Transplant glomerulopathy (TG) is a morphologic lesion of renal 
allografts characterized by duplication of the glomerular basement 
membrane and is widely accepted as a manifestation of chronic 
antibody-mediated rejection (AMR). However, TG is not specific for 
chronic AMR, and this pattern of injury may result from a number of 
disease processes affecting the glomerular endothelium. Baid-Agrawal 
and co-workers consider three different, but not mutually exclusive, 
processes that can produce morphologic lesions of TG: chronic AMR, 
hepatitis C, and thrombotic microangiopathy. 
 Kidney International (2011)  80, 801 – 803.  doi: 10.1038/ki.2011.192 
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 Transplant glomerulopathy (TG) is a mor-
phologic lesion of renal allografts that is 
characterized histologically by duplication 
and / or multilayering of the glomerular base-
ment membrane. It is best appreciated on 
tissue sections stained with silver stains that 
highlight the glomerular basement mem-
brane ( Figure 1 ) and is only infrequently 
seen before 1 year post-transplantation, 1,2 
although earlier lesions may be appreciated 
by electron microscopy. 3 TG, and the closely 
related lesion of peritubular capillary (PTC) 
basement membrane multilayering, are felt 
to represent manifestations of chronic rejec-
tion, particularly chronic antibody-mediated 
rejection (AMR). 4 TG is well documented 
to be associated with the presence of anti-
bodies against the renal allograft , most nota-
bly antibodies against human leukocyte 
antigen class II antigens, and the presence of 
histologic lesions of TG on a renal allograft  
biopsy is a predictor of reduced long-term 
graft  survival. 2,5 
 Sis and co-workers 6 included TG, 
together with PTC basement membrane 
multilayering, PTC C4d deposition, and 
donor-specific antibodies (DSAs), in 
their  ‘ABCD tetrad ’ indicative of chronic-
active AMR in renal allograft s. However, 
only 73 % of their cases of TG were associated 
